99% Purity Recombinant HSA Derived From Rice Same Sequence As Plasma HSA

99% Purity Recombinant HSA Derived From Rice Same Sequence As Plasma HSA

Description

Healthgen Biotech recombinant human serum albumin (OsrHSA) has excellent batch consistency. Using self-pollination rice as the bioreactor to express the OsrHSA, with the world's advanced facility and top production proceeding to extract and purify the OsrHSA, Healthgen Biotech can ensure the excellent consistency of OsrHSA from different batches.

Compared with the plasma HSA, OsrHSA has the same amino acids sequence, molecular weight, N- and C terminus, PI and crystal structure as plasma HSA.

Peptide mapping of OsrHSA and pHSA. Peptide sequences highlighted in bold indicate peptide sequences of HSA sequence in a database. Blue and red letters show the amino acids in OsrHSA and pHSA matched with database sequence, respectively.

Wuhan Healthgen Biotechnology Corp. has been committed in research of protein purification, meanwhile our technology has been patented by the US Patent and Trademark Office on May 15th 2015 and been granted the patent of "A method for isolating and purifying recombinant human serum albumin from transgenic rice grain", which patent number is US9, 023,990. Now, our OsrHSA purity can be as high as 99%. OsrHSA, manufactured in a GMP compliance facility with rigorous quality control procedures, performs superior batch-to-batch consistency.
Compared with the commercial rHSA, Healthgen Biotech OsrHSA has no degradation fragment and fewer polymers.

Supplemental Description

Human serum albumin has been widely used as plasma expansion reagent. Because of its non-enzymatic activity and no immunogenicity, etc. HSA can also be used as excipient and stabilizer in a variety of pharmaceutical preparations and serum-free cell culture medium component. In addition, HSA is also used as a drug carrier due to its antioxidant properties, thereby conferring drugs better physicochemical properties. At present, most HSA products in the market are directly derived from human plasma.

On the one hand, due to the potential existence of various infectious disease pathogens in the human blood, especially AIDS, hepatitis B and other viruses. Thereby, these virus from human plasma will be brought with HSA to the final products. OsrHSA produced by plant derived recombinant proteins technology can effectively avoid the risks of virus pollution and infection. What’s more, the supply of human blood is limited. Therefore, it’s very urgent to search blood substitutes. The establishment and development of recombinant technology provide an important method for the acquisition of biological materials. In recent years, many researchers have been hotly committed to the recombinant human serum albumin research.